Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.
Andrew J. Armstrong(Duke University), Daniel J. George(Duke University), Monika Anand(Duke University), Gabor Kemeny(Duke University), Kris C. Wood(Duke University), Drew G. Gerber(Duke Medical Center), Michael R. Zalutsky(Duke University), Lauren Beth Leith(Duke Medical Center), Susan Halabi(Duke Medical Center), Patrick Healy(Duke University), Wayne Glover(Duke Medical Center), Katie Ware(Duke Medical Center), Catrin Davies(Duke Medical Center), Charles E. Spritzer(Duke University), Colin Rothwell(Duke University), Shiaowen David Hsu(Duke Medical Center), Kelly Mundy(Duke Medical Center), Simon G. Gregory(Center for Human Genetics), Santosh Gupta(Duke University), Jason A. Somarelli(Duke Medical Center)
Cited by 1
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
|Journal of Clinical Oncology|1999|893
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
|Journal of Clinical Oncology|2003|678